Literature DB >> 22766670

11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors.

T Saito1, T Maruyama, Y Muragaki, M Tanaka, M Nitta, J Shinoda, T Aki, H Iseki, K Kurisu, Y Okada.   

Abstract

BACKGROUND AND
PURPOSE: Oligodendroglial tumors with 1p/19q LOH are known to show longer patient survival than those without 1p/19q LOH, but the reason for this clinical difference has not been elucidated, to our knowledge. This study was designed to clarify whether uptake of MET correlates with 1p/19q LOH of oligodendroglial tumors.
MATERIALS AND METHODS: This study included 102 consecutive patients with supratentorial WHO grade II and III oligodendroglial tumors (39 oligoastrocytic and 63 oligodendroglial tumors) that were resected and diagnosed between January 2008 and August 2011 at Tokyo Women's Medical University Hospital. These patients underwent MET PET T/N ratio measurement before treatment. T/N ratios were calculated by dividing the maximum SUV for the tumor by the mean SUV of the contralateral normal frontal cortex. After surgery, FISH for resected tissues was used to determine 1p/19q LOH.
RESULTS: The mean T/N ratio of tumors with 1p/19q LOH was significantly greater than that of tumors without 1p/19q LOH (P = .0166). The threshold T/N ratio value of 2.46 was found to correlate significantly with 1p/19q LOH by univariate (P = .0011) and multivariate analyses (P = .0209) in all tumors.
CONCLUSIONS: The T/N ratio on MET PET might be a useful aid to the diagnosis of 1p/19q LOH. Our data add new information on the biology and imaging characteristics of oligodendroglial tumors with 1p/19q LOH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766670      PMCID: PMC7966311          DOI: 10.3174/ajnr.A3173

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

3.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

Authors:  Martin J van den Bent; Antoine F Carpentier; Alba A Brandes; Marc Sanson; Martin J B Taphoorn; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; Laslo Sipos; Hanny Haaxma-Reiche; Johannes M Kros; Mathilde C M van Kouwenhoven; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

4.  Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas.

Authors:  C Christov; H Adle-Biassette; C Le Guerinel; S Natchev; R K Gherardi
Journal:  Neuropathol Appl Neurobiol       Date:  1998-02       Impact factor: 8.090

5.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.

Authors:  Michael D Jenkinson; Daniel G du Plessis; Trevor S Smith; Kathy A Joyce; Peter C Warnke; Carol Walker
Journal:  Brain       Date:  2006-05-02       Impact factor: 13.501

6.  Positron emission tomography with injection of methionine as a prognostic factor in glioma.

Authors:  O De Witte; I Goldberg; D Wikler; S Rorive; P Damhaut; M Monclus; I Salmon; J Brotchi; S Goldman
Journal:  J Neurosurg       Date:  2001-11       Impact factor: 5.115

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

8.  (11)C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: A stereotactic image-histology comparison.

Authors:  Yoshiko Okita; Manabu Kinoshita; Tetsu Goto; Naoki Kagawa; Haruhiko Kishima; Eku Shimosegawa; Jun Hatazawa; Naoya Hashimoto; Toshiki Yoshimine
Journal:  Neuroimage       Date:  2009-11-24       Impact factor: 6.556

9.  Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.

Authors:  Gurpreet S Kapoor; Timothy A Gocke; Sanjeev Chawla; Robert G Whitmore; Ali Nabavizadeh; Jaroslaw Krejza; Joanna Lopinto; Justin Plaum; Eileen Maloney-Wilensky; Harish Poptani; Elias R Melhem; Kevin D Judy; Donald M O'Rourke
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 10.  Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.

Authors:  Gregory Cairncross; Robert Jenkins
Journal:  Cancer J       Date:  2008 Nov-Dec       Impact factor: 3.360

View more
  15 in total

1.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

Review 2.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

Review 3.  Genetics and imaging of oligodendroglial tumors.

Authors:  Jonathan R Ellenbogen; Carol Walker; Michael D Jenkinson
Journal:  CNS Oncol       Date:  2015-10-19

4.  Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas.

Authors:  Dongwoo Kim; Joong-Hyun Chun; Se Hoon Kim; Ju Hyung Moon; Seok-Gu Kang; Jong Hee Chang; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-17       Impact factor: 9.236

5.  Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma.

Authors:  Egesta Lopci; Marco Riva; Laura Olivari; Fabio Raneri; Riccardo Soffietti; Arnoldo Piccardo; Alberto Bizzi; Pierina Navarria; Anna Maria Ascolese; Roberta Rudà; Bethania Fernandes; Federico Pessina; Marco Grimaldi; Matteo Simonelli; Marco Rossi; Tommaso Alfieri; Paolo Andrea Zucali; Marta Scorsetti; Lorenzo Bello; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-21       Impact factor: 9.236

6.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

7.  Stereotactic image-based histological analysis reveals a correlation between 11C-methionine uptake and MGMT promoter methylation in non-enhancing gliomas.

Authors:  Yoshiko Okita; Tomoko Shofuda; Daisuke Kanematsu; Ema Yoshioka; Yoshinori Kodama; Masayuki Mano; Manabu Kinoshita; Masahiro Nonaka; Shin Nakajima; Toshiyuki Fujinaka; Yonehiro Kanemura
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

Review 8.  Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma.

Authors:  Hirohito Yano; Jun Shinoda; Toru Iwama
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-05-01       Impact factor: 1.742

Review 9.  Imaging of oligodendroglioma.

Authors:  Marion Smits
Journal:  Br J Radiol       Date:  2016-02-05       Impact factor: 3.039

10.  Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.

Authors:  Yasuo Iwadate; Natsuki Shinozaki; Tomoo Matsutani; Yoshio Uchino; Naokatsu Saeki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-02-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.